Human medicines European public assessment report (EPAR): Icatibant Accord, icatibant, Date of authorisation: 16/07/2021, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Nilotinib Accord, nilotinib, Date of authorisation: 22/08/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Tabrecta, capmatinib, Date of authorisation: 20/06/2022, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Roteas, edoxaban, Date of authorisation: 19/04/2017, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Lixiana, edoxaban, Date of authorisation: 19/06/2015, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Kyntheum, brodalumab, Date of authorisation: 17/07/2017, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Itovebi, inavolisib, Date of authorisation: 18/07/2025, Status: Authorised

Zypadhera

Human medicines European public assessment report (EPAR): Enzalutamide Viatris, enzalutamide, Date of authorisation: 22/08/2024, Revision: 3, Status: Authorised